A Review for Dermatofibrosarcoma Protuberans
Main Article Content
Abstract
Dermatofibrosarcoma protuberans (DFSP) stands as the most prevalent cutaneous sarcoma, marked by slow growth and a protuberant papulonodular appearance. Although rare, its impact is significant, necessitating a comprehensive understanding of its characteristics and optimal management. DFSP typically affects adults, though age variability exists, presenting diagnostic challenges. Histological evaluation, often utilizing CD34 immunohistochemical staining, is crucial for accurate diagnosis. The primary treatment modality remains complete surgical excision, emphasizing the importance of generous margins. Imatinib emerges as a valuable therapeutic option for unresectable or metastatic cases. Complementary approaches such as adjuvant radiation therapy and Mohs surgery enhance the treatment armamentarium, allowing for a tailored, multidisciplinary strategy. Regular follow-up is essential for monitoring and addressing potential complications. While local recurrence is a concern, DFSP generally carries a favorable prognosis, especially with early detection and appropriate intervention. Ongoing research continues to refine treatment paradigms, promising improved outcomes for individuals affected by this distinctive cutaneous sarcoma.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Mentzel, T., Beham, A., Katenkamp, D., Dei Tos, A. P., & Fletcher, C. D. (1998). Fibrosarcomatous (" high-grade") dermatofibrosarcoma protuberans: clinicopathologic and immunohistochemical study of a series of 41 cases with emphasis on prognostic significance. The American journal of surgical pathology, 22(5), 576-587.
II. Thway, K., Noujaim, J., Jones, R. L., & Fisher, C. (2016). Dermatofibrosarcoma protuberans: pathology, genetics, and potential therapeutic strategies. Annals of diagnostic pathology, 25, 64-71.
III. Al Barwani, A. S., Taif, S., Al Mazrouai, R. A., Al Muzahmi, K. S., & Alrawi, A. (2016). Dermatofibrosarcoma protuberans: insights into a rare soft tissue tumor. Journal of Clinical Imaging Science, 6.
IV. Hao, X., Billings, S. D., Wu, F., Stultz, T. W., Procop, G. W., Mirkin, G., & Vidimos, A. T. (2020). Dermatofibrosarcoma protuberans: update on the diagnosis and treatment. Journal of clinical medicine, 9(6), 1752.
V. Llombart, B., Serra-Guillén, C., Monteagudo, C., Guerrero, J. A. L., & Sanmartín, O. (2013, February). Dermatofibrosarcoma protuberans: a comprehensive review and update on diagnosis and management. In Seminars in diagnostic pathology (Vol. 30, No. 1, pp. 13-28). WB Saunders.
VI. Reha, J., & Katz, S. C. (2016). Dermatofibrosarcoma protuberans. Surgical Clinics, 96(5), 1031-1046.
VII. Ghazarian, D., Labonte, S., Dickson, B. C., & Al Habeeb, A. (2016). Immunohistology and Molecular Studies of Fibrohistiocytic and Myofibroblastic Cutaneous Tumors. Applied Immunohistochemistry in the Evaluation of Skin Neoplasms, 119-143.
VIII. Bogucki, B., Neuhaus, I., & Hurst, E. A. (2012). Dermatofibrosarcoma protuberans: a review of the literature. Dermatologic surgery, 38(4), 537-551.
IX. McArthur, G. (2007). Dermatofibrosarcoma protuberans: recent clinical progress. Annals of Surgical Oncology, 14, 2876-2886.
X. Drabent, P., & Fraitag, S. (2022). Malignant Superficial Mesenchymal Tumors in Children. Cancers, 14(9), 2160.
XI. Cervini, A. B., Bocian, M., Bujan, M. M., & Stefano, P. (2019). Other Malignant Skin Tumours. Harper's Textbook of Pediatric Dermatology, 1382-1398.
XII. Thway, K., Noujaim, J., Jones, R. L., & Fisher, C. (2016). Dermatofibrosarcoma protuberans: pathology, genetics, and potential therapeutic strategies. Annals of diagnostic pathology, 25, 64-71.
XIII. Iwasaki, T., Yamamoto, H., & Oda, Y. (2019). Current update on the molecular biology of cutaneous sarcoma: dermatofibrosarcoma protuberans. Current Treatment Options in Oncology, 20, 1-16.
XIV. Tsai, Y. J., Lin, P. Y., Chew, K. Y., & Chiang, Y. C. (2014). Dermatofibrosarcoma protuberans in children and adolescents: clinical presentation, histology, treatment, and review of the literature. Journal of Plastic, Reconstructive & Aesthetic Surgery, 67(9), 1222-1229.
XV. Mujtaba, B., Wang, F., Taher, A., Aslam, R., Madewell, J. E., Spear, R., & Nassar, S. (2021). Dermatofibrosarcoma protuberans: pathological and imaging review. Current problems in diagnostic radiology, 50(2), 236-240.
XVI. Elgart, G. W. (2022). Skin Tumors. Tips and Tricks in Plastic Surgery, 609-619.
XVII. Kornik, R. I., Muchard, L. K., & Teng, J. M. (2012). Dermatofibrosarcoma protuberans in children: an update on the diagnosis and treatment. Pediatric Dermatology, 29(6), 707-713.
XVIII. Wiesmueller, F., Agaimy, A., Perrakis, A., Arkudas, A., Horch, R. E., Grützmann, R., & Vassos, N. (2019). Dermatofibrosarcoma protuberans: surgical management of a challenging mesenchymal tumor. World journal of surgical oncology, 17(1), 1-9.
XIX. Lemm, D., Mügge, L. O., Mentzel, T., & Höffken, K. (2009). Current treatment options in dermatofibrosarcoma protuberans. Journal of cancer research and clinical oncology, 135, 653-665.